Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: zax who wrote (248)	7/22/2007 4:29:38 PM
From: tuck	Read Replies (3) \| Respond to of 507

Well, good luck. I'm still watching. It appears Pfizer is flubbing the marketing and promotion of Exubera pretty badly. See: pharmamkting.blogspot.com In the meantime, the only other drug they have a piece of that is in late development is Cimzia, which seems to be bogged down badly at the FDA. The rest of the pipe is interesting, indeed, but rather early. We'll probably get the next earnings CC in a couple of weeks. Should be an interesting call, after the optimism of the previous one. I'm guessing they will try to distance themselves from Exubera a bit more. But then that brings Cimzia into focus. I hope analysts will ask about that, because there just hasn't been any news for months as UCB apparently is negotiating with the FDA about whether or not a new trial will be needed. I'll grant you that with a large slug of cash, and fairly low burn, NKTR can develop its pipe for some time without further dilution. Which is good, because it would suck to have to finance under these conditions. I think NKTR is near, but perhaps not at, the bottom. We need the bad Exubera and Cimzia news out of the way for the bottom to definitely be in. Expectations are already pretty low, though, and I might look to restart a position after the CC, if it does not go well. Cheers, Tuck